Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of LAD106 in healthy volunteers
NL-OMON58802Phase 1Recruiting
- Sponsor
- Almirall
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of LAD106 in Inflammatory Disorders, sponsored by Almirall. Started Feb 2026; status: recruiting.
02
Drugs
LAD106
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on NL-OMON58802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58802.